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A B S T R A C T   
Despite the high heritability of schizophrenia (SCZ), details of its pathophysiology and etiology are still un-
known. Recent findings suggest that aberrant inflammatory regulation and microRNAs (miRNAs) are involved. 
Here we performed a comparative analysis of the global miRNome of human induced pluripotent stem cell 
(iPSC)-astrocytes, derived from SCZ patients and healthy controls (CTRLs), at baseline and following inflam-
matory modulation using IL-1β. We identified four differentially expressed miRNAs (miR-337-3p, miR-127-5p, 
miR-206, miR-1185-1-3p) in SCZ astrocytes that exhibited significantly lower baseline expression relative to 
CTRLs. Group-specific differential expression (DE) analyses exploring possible distinctions in the modulatory 
capacity of IL-1β on miRNA expression in SCZ versus CTRL astroglia revealed trends toward altered miRNA 
expressions. In addition, we analyzed peripheral blood samples from a large cohort of SCZ patients (n = 484) and 
CTRLs (n = 496) screening for the expression of specific gene targets of the four DE miRNAs that were identified 
in our baseline astrocyte setup. Three of these genes, LAMTOR4, IL23R, and ERBB3, had a significantly lower 
expression in the blood of SCZ patients compared to CTRLs after multiple testing correction. We also found 
nominally significant differences for ERBB2 and IRAK1, which similarly displayed lower expressions in SCZ 
versus CTRL. Furthermore, we found matching patterns between the expressions of identified miRNAs and their 
target genes when comparing our in vitro and in vivo results. The current results further our understanding of the 
pathobiological basis of SCZ.   
1. Introduction 
Schizophrenia (SCZ) is a severe mental disorder with a considerable 
disease burden and a lifetime prevalence of nearly 1% (McGrath et al., 
2008; Correll et al., 2015). The main clinical features fall into three 
groups of symptoms: positive symptoms, negative symptoms, and 
cognitive impairments, with a substantial phenotypic heterogeneity 
(Gogtay et al., 2011). Although the currently available pharmacological 
interventions are associated with serious side effects (Patel, 2014) and 
about one-third of patients experience poor long-term outcome (Ijaz 
et al., 2018), they remain the primary treatment approach, especially 
during acute phases (Patel, 2014). Despite the high heritability of SCZ, 
details of its pathophysiology are still unknown. Identification of the 
fundamental disease mechanisms would be essential for the develop-
ment of novel and more effective treatment modalities (Editorial, 2010; 
Rubinstein, 2010). 
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Recent findings suggest that small non-coding RNAs, in particular 
microRNAs (miRNAs), are involved in the pathobiology and symptom 
development of SCZ (Beveridge and Cairns, 2012; Im and Kenny, 2012; 
Xu et al., 2013; Rajman and Schratt, 2017; Cao and Zhen, 2018). miR-
NAs are a class of short (~22 nt) non-coding RNAs that can functionally 
silence, and in some cases enhance, gene expression by complementary 
base-pairing with their relevant mRNA targets. This miRNA-based post- 
transcriptional control can potentially regulate the expression of mul-
tiple downstream target genes in almost all tissues and cell types (Winter 
et al., 2009). The functional importance of miRNA regulatory networks 
in neurodevelopment and brain physiology has been widely studied, and 
recent studies show that these networks play essential roles in SCZ, 
indicating that miRNAs could be utilized as potential biomarkers and 
therapeutic targets (Cao and Zhen, 2018). 
Astrocytes are the most abundant glial cell type in the mammalian 
brain where they perform a wide spectrum of physiological activities, 
many of which are essential in normal brain functioning (Abbott et al., 
2006), such as the immune surveillance of the CNS (Heneka et al., 
2018). In recent years, they have emerged as potential mediators of 
inflammatory and immune-related abnormalities in SCZ (Khandaker 
et al., 2015). For example, studies on astroglia from human postmortem 
samples as well as preclinical animal models implicate a range of 
changes in astrocyte structure and function associated with neuropsy-
chiatric disorders, including increased inflammation in SCZ (Kim et al., 
2018). Neuroinflammation, as a pathophysiological phenomenon, can 
be the outcome of maladaptive or uncontrolled innate immune re-
sponses against various chemical, physical, or microbial danger signals 
in the brain. Neuroinflammation has been linked to dysregulated 
inflammasome activation, a critical component of innate immunity 
(Heneka et al., 2018). Activated inflammasomes induce the release of 
the inflammatory cytokines IL-1β and IL-18 by resident immunocom-
petent glial cells, such as microglia and astroglia (Heneka et al., 2018; 
Singhal et al., 2014; Swanson et al., 2019). These cytokines play a 
pivotal role in activating downstream inflammatory pathways during 
host defense, but have also been suggested to be involved in SCZ and 
other psychiatric disorders when secreted by glial cells in an uncon-
trolled manner (Khandaker et al., 2015). For instance, elevated blood 
and postmortem brain IL-1β levels have been associated with the 
severity and evolution of symptoms in SCZ (Zhu et al., 2018; Moham-
madi et al., 2018). Aberrant inflammatory regulation in astrocytes have 
also been linked to brain volume reduction and cognitive impairment in 
SCZ (Kindler, et al., 2019). Furthermore, miRNAs have recently been 
suggested to be key players in astrocyte and microglia-mediated 
inflammation in SCZ (Mellios and Sur, 2012) and several other CNS 
pathologies (Karthikeyan et al., 2016). 
To date, investigations into the glial biology and immunopathology 
of SCZ have been hindered by the inaccessibility of human brain tissue 
and by the lack of appropriate animal models. The latest methodological 
developments in human induced pluripotent stem cell (iPSC) biology 
have enabled studies of the cellular and molecular features of SCZ 
(Windrem et al., 2017; Falk et al., 2016). Direct reprogramming of fi-
broblasts to iPSCs and their subsequent differentiation into neurons 
(Brennand et al., 2011; Tran, et al., 2013) and astrocytes (Akkouh, et al., 
2020) has been demonstrated to be a relevant and useful in vitro model 
in SCZ research. In the present study, we generated human iPSC-derived 
astroglia from SCZ patients and healthy controls, and used RNA 
sequencing to characterize the SCZ miRNome at baseline and following 
IL-1β-induced inflammatory activation. We identified four highly 
differentially expressed miRNAs which we studied further. In particular, 
we compared the expression of transcripts regulated by these miRNAs in 
the blood of SCZ patients and in astroglial cultures derived from SCZ 
patients and found concordant expression profiles, indicating a potential 
in vivo role for these miRNAs in SCZ. 
2. Materials and methods 
2.1. Recruitment of patients and collection of skin biopsies 
This project is part of the ongoing Norwegian TOP (Thematically 
Organized Psychosis) study. Information about recruitment procedures, 
inclusion and exclusion criteria, and clinical assessments for the TOP 
study as a whole have been described in detail (Mørch et al., 2019; 
Simonsen et al., 2011) (additional details are discussed below). For iPSC 
reprogramming and astrocyte differentiation, fibroblast/skin biopsies 
were isolated from 3 CTRLs and 3 SCZ patients. For gene expression 
measurements of miRNA target genes in whole blood, a subset of the 
TOP sample consisting of 484 SCZ spectrum disorder patients (353 
schizophrenia, 41 schizophreniform, and 90 schizoaffective) and 496 
CTRL subjects was used. These participants were selected based on the 
availability of microarray gene expression data for the relevant markers. 
A detailed description of blood sampling procedures, microarray pre- 
processing, and quality control can be found in a previous report 
(Akkouh et al., 2018). Supplementary Tables S1 and S2 show further 
details about the study participants from whom skin biopsies and whole 
blood samples were obtained, respectively. All patients underwent a 
clinical examination that included diagnostic interviews based on 
Structured Clinical Interview in DSM-IV axis I Disorders (SCID-1) and 
structured assessments of clinical symptoms, use of psychotropic 
medication, smoking habits, alcohol consumption, and illicit substance 
use. Diagnostic evaluation was performed by trained clinical psycholo-
gists and psychiatrists. The main inclusion criteria for patients for both 
skin biopsy collection and for clinical sampling were confirmed diag-
nosis of SCZ according to the Diagnostic and Statistical manual of Mental 
Disorders (DSM)-IV, age between 18 and 65, and ability to give informed 
written consent. The main exclusion criteria were clinically significant 
brain injury, neurological disorder, ongoing infections, autoimmune 
disorders or any form of cancer. All participants have given written 
consent and the study was approved by the Norwegian Scientific Ethical 
Committees and the Norwegian Data Protection Agency. The project has 
been approved by the Regional Ethics Committee of the South-Eastern 
Norway Regional Health Authority (REK#2012/2204). The authors 
assert that all procedures contributing to this work comply with the 
ethical standards of relevant guidelines and regulations. 
2.2. Generation of hiPSCs and differentiation of iPSC-astrocytes 
The main aim of this study was to characterize and to compare the 
astrocyte-specific miRNome in patients with SCZ and in healthy con-
trols. For this, we established a robust hiPSC-astrocyte monoculture 
model with high culture purity. The generation and characterization of 
human iPSCs were carried out as reported previously (Akkouh, et al., 
2020). Astrocytes were differentiated from 3 SCZ and 3 CTRL iPSCs 
following two glial differentiation protocols with small modifications 
(Izrael et al., 2007; TCW et al., 2017) as published earlier (Akkouh, 
et al., 2020). Briefly, we reprogrammed fibroblasts isolated from pa-
tients and CTRLs using Sendai virus vector. On average, 3–5 clones were 
generated per donor iPSC lines and were cultured for at least 5–10 
passages to allow time for the wash-out of virus before pluripotency 
testing. As shown in our previous publication (Akkouh, et al., 2020), 
intra-donor variability was not significant, and therefore one clone per 
donor was selected for experiments. iPSC colonies at passages 24–25 
were transferred to 6-well tissue culture plates in Neural maintenance 
medium (NMM) consisting of 50% DMEM/F12 and 50% Neurobasal 
medium (both from Thermo Fisher) supplemented with 0.5% (v/v) N2, 
1% (v/v) B27 (both from Invitrogen, Carlsbad, CA, USA), 5 μg/ml 
human insulin, 40 ng/ml triiodothyronine (T3), 10 μM β-mercaptoe-
thanol, 1.5 mM L-glutamine, 100 μM NEAA, 100 U/ml penicillin and 
100 μg/ml streptomycin (all from Sigma-Aldrich, St. Louis, MO, USA). 
20 ng/ml EGF and 4 ng/ml bFGF (both from Peprotech, Rocky Hill, NJ, 
USA) were added to the cultures. Astroglia induction was done between 
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days 1–42 using the N2/B27 protocol as described in detail in (Akkouh, 
et al., 2020). For astrocyte maturation and enrichment, NMM medium 
was switched to ScienCell AM medium (ScienCell, Carlsbad, CA, USA) 
on day 42 and cells were further cultured for 60 additional days until 
day 102. Cultures were continuously biobanked from day 42 by freezing 
astrocytes in Sciencell AM medium + 10% DMSO at each passage, and 
storing them in liquid nitrogen. For the monitoring of astroglia differ-
entiation, samples were continuously collected during the differentia-
tion process at days 0 (iPSC), 7, 14, 21, 30, and 40. The mRNA 
expression of PAX6, Nestin, and the astrocyte-specific markers GFAP, 
S100B, SLC1A2, SLC1A3, FABP7, AQP4, ALDH1L1, and ALDOC was 
monitored using a custom-made TLDA gene array card (Thermo Fisher) 
on qPCR platform (Akkouh, et al., 2020). For additional quality control, 
cells were stained with anti-GFAP, anti-S100B and anti-AQP4 antibodies 
(all from Abcam, Cambridge, UK) and were analyzed using fluorescent 
microscopy on day 42 (GFAP) and day 102 (GFAP, S100B, AQP4). 
Finally, functional characterization of iPSC-astroglia was done using a 
glutamate uptake assay, and astrocytes were considered mature and 
were used for experiments on day 102 (Akkouh, et al., 2020). Each in 
vitro experiment was done in triplicates if not stated otherwise. 
2.3. Inflammatory modulation of astrocytes 
To mimic inflammasome activation in vitro, day 102 astrocytes were 
treated with 3 relevant working concentrations of IL-1β (0.1, 1, and 10 
ng/ml; Peprotech) and the short-term (4 h) effect on early-response 
inflammatory cytokine genes were investigated using qPCR (Akkouh, 
et al., 2020). Since all applied concentrations strongly increased the 
expression of CXCL8/IL-8, IL6, and TNF genes in both SCZ and CTRL 
iPSC-astrocytes with no differences between patient and control lines, 
and since the most pronounced effect was seen at an IL-1β concentration 
of 10 ng/ml (Akkouh, et al., 2020), this concentration was therefore 
used in subsequent experiments. Cell pellets were collected after 4 h of 
incubation for miRNA extraction. Harvested samples were either 
immediately used for analyses or stored at − 80 ◦C. 
2.4. RNA extraction and miRNA sequencing 
Total RNA was extracted from the mature astrocyte samples using 
the MagMax mirVana Total RNA Isolation Kit (Thermo Fisher) according 
to manufacturer’s instructions. Approximately 1 million cells were used 
as input. RNA yield was quantified with a NanoDrop 8000 Spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA) and RNA 
integrity was assessed with Bioanalyzer 2100 RNA 6000 Nano Kit 
(Agilent Technologies, Santa Clara, CA, USA). All samples had an RNA 
Integrity Number (RIN) > 8.5. Library preparation and single-end 
miRNA sequencing were carried out at the Norwegian High- 
Throughput Sequencing Centre (www.sequencing.uio.no). Briefly, li-
braries were prepared with the QIAseq miRNA Library Kit (QIAGEN), 
which integrates Unique Molecular Indices (UMIs) into the reverse- 
transcription process to eliminate PCR and sequencing bias. The pre-
pared samples were then sequenced on an Illumina NextSeq 500 plat-
form (Illumina) at an average depth of 22 million reads per sample using 
a read length of 75 base pairs single-end. 
2.5. Data processing 
Sequencing data were processed with the GeneGlobe Data Analysis 
Center (QIAGEN), which allowed us to make use of the integrated UMIs 
to identify individual miRNA species. First, Cutadapt (Martin, 2011) was 
used to trim reads for 3′ adapter sequences and low-quality bases, and 
then insert sequences and UMI sequences were identified. Reads with 
less than 16 bp insert sequences or less than 10 bp UMI sequences were 
discarded. Following trimming and cleaning, a sequential two-step 
alignment strategy was followed to map the reads to different data-
bases. In the first step, reads were sequentially mapped to multiple 
references (miRbase mature, miRbase hairpin, piRNA, tRNA, mRNA and 
other RNA) allowing only perfect matches. In the second step, un-
mapped sequences from the first step were mapped to miRbase mature 
tolerating up to two mismatches. For miRNA mapping, miRbase v21 was 
used as reference, while piRNABank was used for piRNA mapping. For 
the remaining RNA species, the human GRCh38 reference was used. 
Mapping was performed with Bowtie (Langmead et al., 2009). Read 
counts were calculated for each RNA category from the mapping results. 
2.6. Differential expression analysis 
Differential expression (DE) analysis was carried out using only the 
read counts for mature miRNAs that were considered unique as identi-
fied by the UMIs. A pre-filtering step was applied in which only miRNAs 
with more than one count per million (CPM) in at least three samples 
(the least group size) were retained, leaving 1200 out of 1599 (75%) 
mature miRNA transcripts for downstream analyses. The statistical R 
package DESeq2 (Love et al., 2014) was used for DE analyses applying 
default parameters. Four separate DE analyses were performed to 
examine the following: 1) baseline (untreated) differences between 
CTRL and SCZ astrocytes; 2) the effects of cytokine treatment (untreated 
vs. treated) in CTRL samples; 3) the effects cytokine treatment (un-
treated vs. treated) in SCZ samples; and 4) the effects of cytokine 
treatment across diagnostic groups (CTRL (untreated vs. treated) vs. SCZ 
(untreated vs. treated)). Sex and age differences were controlled for in 
1), while in 2) and 3) the samples were paired and therefore perfectly 
matched on sex and age. In 4), the design formula was modified to take 
into account the fact that samples were nested within diagnostic groups, 
and this precluded the possibility of controlling for additional variables. 
An miRNA was defined as DE if the FDR was <0.1. 
2.7. Target prediction and gene ontology enrichment analysis 
Target prediction for significant miRNAs was performed with the R 
package miRNAtap, which integrates and aggregates ranked miRNA 
target predictions from five of the most commonly cited prediction al-
gorithms: DIANA-microT (Maragkakis, et al., 2011), miRanda (Enright, 
et al., 2003), PicTar (Lall et al., 2006), TargetScan (Friedman et al., 
2009), and miRDB (Wong and Wang, 2015). Default parameters were 
applied. The full set of ranked gene targets were then used as input to the 
R package topGO for Gene Ontology (GO) enrichment analysis. “Bio-
logical Process” was selected as the ontology and the Kolomonogorov 
Smirnov (KS) method was used for enrichment testing in order to make 
use of the rank information. A GO term was considered significantly 
enriched if the nominal p-value was <0.01, which is the default behavior 
of topGO. 
2.8. ELISA assays 
For sample preparation, 2.5 × 105 cells were cultured in 1 ml AM 
medium in 12-well plate. Culture supernatants were harvested 24 h after 
activation by 10 ng/ml IL-1β and the concentration of IL-6 and TNF- 
alpha cytokines were measured using Human IL-6 and TNF alpha 
ELISA kits (Thermo Fisher) following the manufacturer’s recommen-
dations. The precision of the ELISA kits were the following: Intra-Assay 
variation: CV < 10%; Inter-Assay variation: CV < 12% (CV% = SD/ 
meanX100). 
2.9. Statistics 
To test for significant differences in the blood gene expression levels 
of relevant miRNA target genes (NFE2L2, FCGR1A, FCGR1B, FCGR1CP, 
IGF1, IRAK1, GSK3B, IL2, IL23, IL23R, LAMTOR4, MTOR, ERBB2, 
ERBB3, ERBB4, PIK3CA) in SCZ patients compared to CTRLs, a multiple 
linear regression model with adjustment for age and sex differences was 
performed in R 3.4.1. Since some of the genes are represented by 
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multiple probes on the microarray chip, a total of 25 markers were tested 
(Suppl. Table S9). The selection of miRNA target genes was based on our 
target prediction results in combination with manual literature searches. 
3. Results 
3.1. Summary of miRNA sequencing output 
An overview of the miRNA sequencing output can be found in Suppl. 
Fig. S1. Briefly, the average sequencing coverage was ~22 million reads 
per sample (Suppl. Fig. S1A), of which an average of ~25% (8–36%) 
mapped to miRNA genes (Suppl. Fig. S1B). When only mappable reads 
are considered, the miRNA fraction increases to 49%. We found no 
correlation between sequencing coverage and the percentage of miRNA 
reads. On average, ~84% of total miRNA reads were UMIs (Suppl. 
Fig. S1C). After filtering out lowly expressed miRNAs, 1200 genes were 
considered detected and thus tested in downstream analyses. 
Fig. 1. Differential expression of miRNAs in SCZ iPSC-astroglia at baseline. A) PCA plots of baseline (untreated) astrocyte cultures. A clear separation on diagnosis is 
observed when clustering across PCs 3 and 4, explaining a relatively small proportion (17%) of the gene expression variance. All miRNA genes with detectable 
expression levels (n = 1200) were used as input. B) Volcano plot showing effect sizes (log fold changes) and raw p-values for the four miRNAs with differential 
expression in SCZ astrocytes compared to controls. C) Box plots of significant miRNAs. Black data points represent individual samples within each group. D) Top 10 
genes predicted to be targets of the identified differentially expressed miRNAs. The target genes are ranked based on prediction results from five different sources as 
implemented in the miRNAtap tool. No target genes were identified for miR-1185–1-3p. E) GO enrichment analysis of the full set of predicted target genes for the 
indicated miRNAs. Only the top GO terms with lowest p-values are shown. For the full list, see Supplementary Table S4. 
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3.2. Differential expression of miRNAs in iPSC-astroglia at baseline 
Recent advances suggest that certain miRNA classes are involved in 
the pathophysiology and symptom development of SCZ (Beveridge and 
Cairns, 2012; Im and Kenny, 2012; Xu et al., 2013; Rajman and Schratt, 
2017; Cao and Zhen, 2018). To date however, little is known about 
exactly which miRNA species and their gene targets underlie putative 
cellular pathomechanisms. Therefore, we first performed an unbiased 
screening of the complete miRNome of human iPSC-astrocytes at base-
line from both healthy CTRLs and SCZ patients (Fig. 1). 
3.2.1. Unsupervised clustering 
We used principal component analysis (PCA) to cluster astrocyte 
samples based on all detected miRNAs (n = 1200). An incomplete sep-
aration on diagnosis was observed when clustering over the first two 
principal components (PCs), explaining 79% of the variation (Fig. 1A). 
The separation between CTRL and SCZ miRNomes became more pro-
nounced when clustering over PC3 and PC4, but the explained total 
variation was only 17%, indicating that diagnostic status is not the 
major source of variation in miRNA gene expression (Fig. 1A). 
3.2.2. DE analyses between CTRL and SCZ groups 
We idientified four miRNA genes with clear differential expression 
(FDR < 0.1) in SCZ astroglia, all of which exhibited substantially lower 
baseline expression compared to CTRL astroglia: miR-337-3p, miR-127- 
5p, miR-206, and miR-1185–1-3p (Fig. 1B-C; Suppl. Table S3). Strik-
ingly, all of these significant DE miRNAs have previously been linked to 
the regulation of inflammation at both cellular and systems levels (Xia 
et al., 2018; Xie et al., 2012; Akehurst et al., 2015; Chu et al., 2019; 
Garcia-Lacarte et al., 2019). To identify the biological processes in 
which the four miRNAs are involved, we first searched for the potential 
target genes using multiple target prediction databases and then per-
formed a GO enrichment analysis on the ranked targets (Fig. 1D). We 
found the strongest enrichment in target gene sets related to cell adhe-
sion interactions and regulation of neurogenesis (miR-127-5p), protein 
transport and growth processes (miR-206), and regulation of trans-
membrane ion transport (miR-337-3p) (Fig. 1E; Suppl. Table S4). No 
target genes were identified for miR-1185–1-3p. 
3.3. Effects of inflammatory modulation on the miRNome of iPSC- 
astrocytes 
Glial cells, such as astrocytes, have recently emerged as potential 
candidates for brain inflammatory abnormalities in SCZ (Khandaker 
et al., 2015), and changes in human postmortem brain IL-1β levels have 
been identified as potential biomarkers in SCZ pathophysiology (Zhu 
et al., 2018; Mohammadi et al., 2018). These findings resonate with 
recent reports linking dysregulated inflammatory responses in astro-
cytes to cortical atrophy and cognitive impairment in SCZ (Kindler, 
et al., 2019). Although miRNAs have been proposed to play an impor-
tant role in astroglia-mediated inflammation in CNS pathologies (Kar-
thikeyan et al., 2016) including SCZ (Mellios and Sur, 2012), very little 
is known about their glia-specific expressions following inflammatory 
challenge. Therefore, we modelled an inflammatory environment by 
treating iPSC-astrocytes with IL-1β, a classical and prototypical pro- 
inflammatory cytokine, as described in our previous study (Akkouh, 
et al., 2020). 
As expected, PCA of treated and untreated samples showed a 
Fig. 2. Effects of cytokine treatment on miRNA expression in iPSC-astrocytes. A) PCA plots of all IL-1β-treated (trt) and untreated (untrt) samples. Clustering over the 
first two components show that donor effects are a major source of variance as samples from the same individual tend to cluster together. A clear separation on 
cytokine treatment and diagnosis is only seen when samples are clustered over PCs 3 and 4. B-C) Volcano and box plots showing the one miRNA (miR-146a-5p) that 
was significantly up-regulated by cytokine treatment in SCZ samples. D-E) Volcano and box plots showing three miRNA that were up-regulated by cytokine treatment 
in CTRL samples. The volcano plots were based on all miRNAs with detectable expression levels (n = 1200). The black data points in the box plots represent in-
dividual samples. 
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considerable separation on donors when clustering over the first two 
PCs, accounting for 79% of the total variation (Fig. 2A). Clustering over 
PC3 and PC4 revealed a clear albeit modest (11%) separation on IL-1β 
treatment and diagnostic status (Fig. 2A). These observations are in line 
with similar studies showing that donor effects are a greater source of 
variance than diagnostic status in iPCS-derived cellular models (Read-
head et al., 2018). 
3.3.1. DE analyses in CTRL and SCZ groups following inflammatory 
stimulation 
We next performed two separate DE analyses examining the miRNA 
expression-modulatory effects of IL-1β treatment in SCZ and CTRL 
samples, respectively. In the SCZ group, IL-1β significantly changed the 
expression level of miR-146a-5p (Fig. 2B-C; Suppl. Table S5). In the 
CTRL group, the treatment modulated the expression of miR-146a-3p, 
miR-146a-5p, and miR-4485-3p (Fig. 2D-E; Suppl. Table S6). GO 
enrichment analysis of predicted miR-146a-3p target genes (Suppl. 
Fig. S2A) revealed significant enrichment for gene sets related to clas-
sical biochemical components of the cellular stress reponse, such as 
regulation of several biosynthetic processes as well as organelle and 
actin cytoskeleton organization (Suppl. Fig S2B). 
3.3.2. Group-specific effects of cytokine treatment on miRNA expression 
To investigate whether SCZ iPSC-astrocytes respond differently to IL- 
1β treatment than CTRL astrocytes, we performed a group-specific DE 
analysis. Overall, five miRNAs were differentially modulated by cyto-
kine treatment across diagnostic groups; however, these differences 
were only trending (p > 0.05) and did not survive correction for the 
number of tests performed (Fig. 3A; Suppl. Table S7). Two of the sug-
gestive miRNAs, miR-188-3p and miR-1908-5p, showed similar 
expression trends in both CTRL and SCZ, where IL-1β treatment 
modestly decreased their levels in CTRLs and increased their expression 
in SCZ astrocytes (Suppl. Fig. S3). Secondly, miR-3174 and miR-614 also 
exhibited similar expression patterns, as IL-1β slightly increased their 
levels in CTRL, but not in SCZ astroglia (Suppl. Fig. S3). Finally, we did 
not observe any modulatory effect of the treatment on miR-493-3p 
levels, neither in CTRL nor in SCZ (Suppl. Fig. S3), neither did we 
observe significant differences in the IL-1β-induced IL-6 and TNF-alpha 
secretion of astrocytes between cases and controls (Suppl. Fig. S4). GO 
analysis of the predicted target genes (Fig. 3B) showed the strongest 
enrichment for biological processes involved in the control of cell pro-
liferation (miR-188-3p) and in the negative regulation of transcription, 
translation and macromolecule biosynthesis (miR-493-3p) (Fig. 3C; 
Suppl. Tabl S8). Enrichments for biological activities pertaining to the 
regulation of apoptotic processes (miR-1908-5p) were also observed 
(Fig. 3C; Suppl. Tabl S8). The target genes for miR-3174 and miR-614 
(Fig. 3B) were not significantly enriched for any GO terms. 
3.4. Expression of target genes in circulating immune cells matches the 
expression patterns of their targeting miRNAs in in vitro iPSC-astrocyte 
cultures 
Astrocytes secrete a diverse range of miRNAs contained in exosomes 
(Jovicic and Gitler, 2017), which can pass the blood–brain barrier, and 
this mechanism has been hypothesized as a form of remote target gene 
regulation between the CNS and circulation, as well as a possible way for 
brain-immune bidirectional communication (Matsumoto et al., 2018; 
Saint-Pol et al., 2020). Furthermore, the diagnostic value of circulating 
miRNAs isolated from total peripheral blood samples has recently been 
proposed in SCZ (Liu et al., 2017). We thus examined peripheral blood 
Fig. 3. Group-specific effects of cytokine treatment on miRNA expression. A) Five miRNAs displayed a suggestive (p < 0.05) disease-specific association with 
cytokine treatment, i.e. IL-1β modulated the expression of these miRNAs differently in SCZ astrocytes than in CTRL astrocytes. B) The top 10 target genes of the five 
identified miRNAs as predicted by aggregating results from multiple prediction algorithms. C) GO enrichment test using the full set of predicted target genes for each 
suggestive miRNA. Only the most significantly enriched GO terms are shown. No GO term was significantly enriched by the predicted target genes of miR-3174 and 
miR-614. 
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samples from a large cohort of SCZ patients (n = 484) and healthy CTRLs 
(n = 496) and tested whether a selected panel of target genes (see Ma-
terials and Methods) for the four DE miRNAs identified in our baseline 
astrocyte cultures (Fig. 1A-C) were differentially expressed between 
diagnostic groups. We found that three genes, LAMTOR4, IL23R, and 
ERBB3, had a significantly lower expression in the blood of SCZ patients 
relative to CTRLs after multiple testing correction (FDR < 0.1; Fig. 4; 
Suppl. Table S9). In addition, trending differences (p < 0.05) were found 
for two other genes, ERBB2 and IRAK1, both of which had lower 
expression levels in SCZ versus CTLR (Fig. 4; Suppl. Table S9). 
Notably, when comparing our in vivo and in vitro results (Figs. 1 and 
4), we found matching patterns between the expression of miRNAs and 
their target mRNAs. The blood expression levels of the selected targets of 
all four miRNAs, which exhibited lower expression in SCZ iPSC-astroglia 
versus CTRL at baseline, were also lower in SCZ blood samples relative 
to healthy control samples: miR-337-3p and LAMTOR4, miR-1185-1-3p 
and IL23R, miR-127-5p and ERBB2/ERBB3, and miR-206 and IRAK1 
(Fig. 1C and Fig. 4) (Akehurst et al., 2015; Chu et al., 2019; Wang et al., 
2014). These findings indicate a possible SCZ-specific alteration in top- 
down brain-immune system regulation of genes involved in innate im-
mune responses (IL23R; IRAK1) and in cellular proliferation and meta-
bolism (ERBB3, ERBB2, LAMTOR4). 
4. Discussion 
A mounting body of evidence suggests that certain miRNA classes are 
involved in the pathophysiology and symptom development of SCZ 
(Beveridge and Cairns, 2012; Im and Kenny, 2012; Xu et al., 2013; 
Rajman and Schratt, 2017; Cao and Zhen, 2018). A good example is miR- 
137, which has an important role in modulating neuronal maturation, 
neurotransmission, and synaptic plasticity, and for which dysregulation 
has been linked to SCZ, bipolar disorder, and to the cognitive symptoms 
of various psychiatric disorders (Thomas et al., 2018). Dysregulation in 
the expression of certain miRNA species and of exosomal miRNA-cargo 
in astrocytes and microglia has been linked to neurotoxic inflammation 
in neurodegenerative disorders, such as amyotrophic lateral sclerosis 
(ALS) (Varcianna et al., 2019; Rostalski et al., 2019). Furthermore, 
recent reports exposed several miRNAs as potential culprits in astrocyte 
and microglia-mediated neuroinflammation in SCZ (Mellios and Sur, 
2012) and other brain pathologies (Karthikeyan et al., 2016). However, 
our knowledge is still scarce about the exact miRNA species and their 
gene targets that mediate glial functions and glia-neuron crosstalk in 
SCZ. 
In the present study, our goal was to obtain the complete miRNome 
of human iPSC-astrocytes at baseline and following inflammatory 
stimulation. We identified four miRNAs, miR-127-5p, miR-206, miR- 
337-3p and miR-1185–1-3p, which displayed lower expression in SCZ 
astroglia expressions relative to CTRL astroglia. All four of these miRNAs 
are involved in the regulation of inflammation in various systemic and 
tissue microenvironment-specific contexts (Xia et al., 2018; Xie et al., 
2012; Akehurst et al., 2015; Chu et al., 2019; Garcia-Lacarte et al., 
2019). We then ran gene enrichment analyses to gain insight into the 
biological processes the four miRNAs may regulate. We found that the 
strongest enrichments were associated with neurogenesis and cell-to- 
cell adhesion processes (miR-127-5p), protein transport and growth 
modulation (miR-206), and control of transmembrane ion transport 
(miR-337-3p). These biological processes can be linked to the astroglial 
regulation of neuroplasticity (Haydon and Nedergaard, 2015) 
Fig. 4. Differential expression analysis of selected target genes in circulating immune cells. A selected panel of predicted targets of the four miRNAs with differential 
expression in baseline SCZ astrocytes were examined in whole blood samples from SCZ patients (n = 484) and healthy CTRLs (n = 496) using microarrays. A total of 
25 probes representing 16 individual genes were examined. Three genes, LAMTOR4, IL23R, and ERBB2, were significantly (FDR < 0.1) down-regulated in SCZ cases, 
while ERBB2 and IRAK1 displayed a nominally significant (p < 0.05) down-regulation in SCZ. **FDR < 0.1. *p-value < 0.05. The gene names in brackets represent 
gene-targeting miRNAs based on in silico predicition algorithms and available literature. 
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suggesting that decreased expression of the four miRNAs may be 
involved in the aberrant formation and sculpting of neural tissue as well 
as the impaired neuroplasticity observed in SCZ (Bhandari et al., 2016). 
In line with our findings, down-regulation of two miR-127 analogs, miR- 
127-3p and 5p, has been demonstrated in frontotemporal dementia 
(Piscopo et al., 2018) and in the prefrontal cortex of Parkinson’s Disease 
patients (Hoss et al., 2016), respectively, suggesting a pathobiological 
role for these miRNA species in the cognitive symptoms of different 
neuropsychiatric disorders. It has also been reported that expression of 
miR-206 in the brain shows significant allelic association to SCZ (Han-
sen et al., 2007; Hauberg et al., 2016). Furthermore, down-regulation or 
miR-337-3p has been shown to play a role in synaptic abnormalities in a 
mouse model of SCZ by potentially influencing the onset of age-related 
cognitive decline observed during the symptom evolution of the disor-
der (Earls et al., 2012). miR-337 is also one of the clozapine-associated 
miRNAs previously shown to influence ligand-receptor interactions at 5- 
HT2A serotonin receptor sites (Santarelli et al., 2013). While we found 
no target genes for miR-1185-1-3p in our enrichment analysis, down- 
regulation of this miRNA has been seen in depression (Zhang et al., 
2016) and has been suggested to be involved in the negative symptoms 
of SCZ (van den Berg et al., 2020). Our results corroborate these findings 
by showing a decreased baseline expression of miR-127-5p, miR-206, 
miR-337-3p, and miR-1185-1-3p in SCZ-astrocytes, suggesting a cell 
type-specific role of these miRNA species in SCZ pathogenesis. 
The gliopathy hypothesis of SCZ is an emerging paradigm in psy-
chiatry research that implicates glia-related inflammatory abnormal-
ities, such as abnormal brain IL-1β levels, in disease pathophysiology 
(Khandaker et al., 2015; Zhu et al., 2018; Mohammadi et al., 2018). 
Recent findings associate dysregulated inflammatory responses in as-
trocytes with cortical atrophy and cognitive impairment in SCZ (Kindler, 
et al., 2019). miRNAs have been causally linked to astroglia-mediated 
inflammation in CNS pathologies (Karthikeyan et al., 2016) including 
SCZ (Mellios and Sur, 2012), but very little is known about their 
astrocyte-specific expressions following inflammatory modulation. 
Therefore, we next treated iPSC-astrocytes with IL-1β, and performed 
two separate DE analyses examining the miRNA expression-modulatory 
effects of the treatment in SCZ and CTRL samples. We found that IL-1β 
significantly changed the expression level of only one miRNA species, 
miR-146a-5p, in the SCZ group. This is in good agreement with recent 
studies reporting miR-146a as an IL-1β-responsive element (Nahid et al., 
2015), and an inflammatory biomarker miRNA involved in the regula-
tion of a plethora of innate immune responses (Nahid et al., 2011; Saba 
et al., 2014). In the CTRL group, by contrast, IL-1β significantly changed 
the expression levels of three miRNA species: miR-146a-3p, miR-146a- 
5p, and miR-4485-3p, all of which have also been associated with 
inflammation and related cellular stress responses in previous in vitro 
and in vivo studies (Nahid et al., 2015, 2011; Saba et al., 2014). miR- 
4485 has also been associated with inflammatory responses following 
different environmental insults, such as heat-shock (Rong and Liu, 2020) 
and UV irradiation (Hwang et al., 2020). Notably, SCZ astrocytes 
exhibited a much lower degree of IL-1β-provoked upregulation of miR- 
146a-5p than CTRL astrocytes, suggesting a decreased ability to 
respond to inflammatory stress. In line with these findings, our GO 
enrichment analysis of predicted miR-146a-3p target genes showed 
significant enrichments for classical biochemical components of cellular 
stress reponse, such as regulation of several biosynthetic processes as 
well as organelle and actin cytoskeleton reorganization. The observed 
disparate expression of miRNAs following IL-1β modulation in SCZ and 
CTRL astrocytes suggests an impaired ability of SCZ-astroglia to respond 
to inflammatory challenge, and an overall decrease in stress resilience 
compared to CTRLs. 
To further investigate if there is a difference in the response to IL-1β 
treatment in SCZ versus CTRL astrocytes, we performed a group-specific 
DE analysis. We found only trending, but not significant differences in 
the expression of five miRNA species, which were differentially modu-
lated by the inflammatory treatment across diagnostic groups, and no 
differences in the IL-1β-induced inflammatory cytokine secretion of as-
trocytes. It is important to note that this latter phenomenon may be an 
inssue of statistical power due to low donor numbers (n = 3) between 
SCZ and CTRLs. Two of the five miRNAs, miR-188-3p and miR-1908-5p, 
displayed moderate trends in which both were downregulated by IL-1β 
treatment in CTRLs, but upregulated in SCZ astrocytes. Interestingly, 
abnormal upregulations of both miR-188 and miR-1908 have been 
associated with neurodegenerative disorders (Jovicic and Gitler, 2017; 
Wang et al., 2018). miR-188 has recently been shown to be enriched in 
astroglia in a mouse model of ALS, a neurodegenerative disorder in 
which astrocytes play a crucial role in disease pathogenesis (Jovicic and 
Gitler, 2017). In addition, upregulation of miR-1908 has been shown to 
impair amyloid clearance by targeting ApoE, and elevated levels of this 
miRNA has been found in peripheral blood cells of Alzheimer’s disease 
patients (Wang et al., 2018, 2019). This is suggestive of a dysregulated 
astrocytic response to infections or chronic inflammation in SCZ, where 
abnormally high levels of miR-188 and miR-1908 may predispose pa-
tients to neurodegeneration. Two other miRNAs, miR-3174 and miR- 
614, exhibited increased expression levels in CTRL, but not SCZ astro-
cytes following inflammatory modulation. miR-3174 and miR-614 have 
been shown to drive (Li et al., 2017) and inhibit (Zhang et al., 2018) 
apoptosis and autophagy in cancer cells, respectively. Both processes are 
also well known during and after inflammatory stress responses in the 
human brain (Corps et al., 2015), and are central to the survival and 
post-stress functions of astrocytes following brain injuries, inflammation 
and oxidative stress (Karve et al., 2016). Our results indicate an inability 
of SCZ astrocytes to regulate the expression of these cell survival-related 
miRNAs under inflammatory conditions. It is important to note that the 
lack of statistical significance in our DE analyses may be due to small 
sample sizes, and therefore warrants further investigation into the 
modulatory effects of IL-1β on the levels of the identified miRNAs in 
human astrocytes. 
The exosome-mediated astroglial secretion of miRNAs and their 
transportation via the blood–brain barrier is a putative mechanism that 
may allow the glial compartment of the brain to communicate with and 
regulate gene expression in peripheral immune cells (Jovicic and Gitler, 
2017; Matsumoto et al., 2018; Saint-Pol et al., 2020). This hypothesis is 
gaining ground in recent psychoneuroimmunological research, empha-
sizing the potential diagnostic value of circulating miRNAs in SCZ (Liu 
et al., 2017). To investigate a possible astrocyte-peripheral immune 
regulatory axis in SCZ, we examined peripheral blood samples from a 
large cohort of SCZ patients (n = 484) and healthy CTRLs (n = 496). 
Screening for a selected panel of genes that are targets of the four 
differentially expressed miRNAs previously identified in our iPSC- 
astrocyte baseline setup, we found that three of these genes, LAM-
TOR4, IL23R, and ERBB3, displayed significantly lower expressions in 
the blood of SCZ patients relative to CTRLs after multiple testing 
correction. We also found a trend for lower expression of ERBB2 and 
IRAK1 in SCZ patients versus CTLRs. Thus, our clinical in vivo and iPSC in 
vitro results showed matching expression patterns between the four 
miRNAs and their target genes, supporting the notion of a top-down 
brain-immune system regulatory mechanism with disease-specific al-
terations in SCZ. Interestingly, the modulated target genes in the clinical 
sample were factors critically involved in innate immune responses 
(IL23R, IRAK1) (Mogensen, 2009; Szabo and Rajnavolgyi, 2013), 
cellular metabolism and cell cycle regulation, but also in the immune 
control of pathogenic infections (ERBB3, ERBB2, LAMTOR4) (Ho et al., 
2017). The observed lower expression of these genes in SCZ patients 
may represent miRNA-based transcriptional gene activation where miRNAs 
bind nascent RNA transcripts, gene promoter regions, or enhancer re-
gions and positively regulate gene expression, thus decreased trends in 
miRNA expression are expected to be associated with decreased 
expression of their gene targets (Orang, 2014; O’Brien et al., 2018). It 
may also involve abnormal secretion of exosomes and/or disparate 
amounts of miRNA cargo-load in SCZ-astroglia secreted exosomes 
(Jovicic and Gitler, 2017). The phenomenon may also be the result of 
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dysregulated peripheral immunity, but can also be the consequence of a 
compensatory mechanism seen in long-term, chronic inflammatory 
conditions (Fekete et al., 2012). For instance, chronic inflammatory 
stimulation of dendritic cells, a myeloid cell type that plays a critical role 
in bridging innate and adaptive immunity, has been linked to sustained 
IRAK1 suppression (Hedl et al., 2007). The same phenomenon was 
observed in monocytes of septic patients (Escoll et al., 2003). Further-
more, bacterial LPS-induced miRNAs have been shown to act via down- 
regulation of the innate immune Toll-like receptor signaling component 
of IRAK1 through miR-146a (Taganov, 2006). This represents an evo-
lutionally conserved immune tolerance mechanism that may be 
involved in the detected SCZ-specific expression patterns of miRNAs and 
gene targets, and may also support the inflammatory gliopathy hy-
pothesis of SCZ, where chronic, low-grade inflammation may play a 
causative role in the anomaly (Khandaker et al., 2015). 
In summary, we performed a comparative analysis of the global 
miRNome of human astrocytes differentiated from iPS cells derived from 
SCZ patients and healthy controls, at both baseline and following in-
flammatory modulation. We identified four differentially expressed 
miRNAs in SCZ astrocytes that exhibited significantly lower baseline 
expression relative to CTRLs, and indications of differential inflamma-
tory modulation. We also analyzed peripheral blood samples from a 
large cohort of SCZ patients and healthy controls and found patterns of 
expression of these four miRNAs and their target genes that matched our 
in vitro results. These data have implications for the role of astroglia and 
a hypothesized astroglia-peripheral immune regulatory axis in the 
pathogenesis of SCZ. 
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